pathway is another important cell-proliferation pathway downstream of EGFR that is frequently activated in cancer. Although mutations in Ras oncogenes do not seem to coexist with EGFR mutations ...

In this video, Xiuning Le, MD, PhD, discusses how the definition of EGFR-mutated lung cancer has expanded in recent years.

[28] Two pathways thought to be relevant in the ... intracellular molecular effectors downstream to EGFR; and (iv) EGFR gene mutations or loss of the target. EGFR TKI plus EGFR MAb, multi-ErbB ...

In this video, Xiuning Le, MD, PhD, discusses some of the latest developments in the study and treatment of EGFR-mutated lung cancer.

Alternative RTK pathways that are activated following EGFR inhibition is another area ... and as yet undiscovered mutations. Advancing our knowledge of specific cellular and molecular mechanisms ...

BH-30643 is an OMNI-EGFR inhibitor that targets classical, atypical, and compound EGFR mutations and acquired resistance mutations in HER2.

J&J is trying to supplant AstraZeneca's blockbuster Tagrisso, a once-daily pill that has transformed the treatment of non-small cell lung cancer with EGFR mutations. It remains to be seen how many ...

Three years later, Rybrevant gained its first FDA nod, to treat NSCLC patients with exon 20 insertion mutations ... blocking the EGFR and mesenchymal-epithelial transition (MET) pathways.

As monotherapy for treatment of adult patients with advanced NSCLC with activating EGFR exon 20 insertion mutations, after failure of platinum-based therapy.